Farmácia/Notícias da Indústria
M-A | Benefícios e riscos do início rápido de terapia antirretroviral em pacientes com HIV.
22 Jun, 2022 | 21:10hEstudo randomizado por cluster | Avaliação de intervenção multicomponente composta de educação e resposta para reduzir a prescrição de benzodiazepínicos por clínicos gerais.
22 Jun, 2022 | 20:52hDiretriz provisória da OMS sobre o uso de vacinas contra COVID-19 atualizadas para as variantes.
21 Jun, 2022 | 13:12hVer também: Interim statement on the composition of current COVID-19 vaccines – World Health Organization
Comentário no Twitter (fio – clique para saber mais)
Current #COVID19 vaccines provide high levels of protection against severe disease and death from all variants. They should continue to be used.
🆕 interim statement:https://t.co/bVzzx1HnG2 pic.twitter.com/CJlAJqFr3C
— World Health Organization (WHO) (@WHO) June 17, 2022
[Preprint] Estudo randomizado aberto | Baricitinibe é não inferior ao tocilizumabe em pacientes internados com COVID-19 grave.
21 Jun, 2022 | 13:01hConteúdos relacionados:
WHO recommends two new drugs to treat COVID-19 – World Health Organization
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine
Comentário no Twitter
Preprint⚡⚡
Baricitinib Vs Tocilizumab open label RCT
Baricitinib was non-inferior to tocilizumab with regards to the composite outcome of mechanical ventilation or death by day 28 and the time to discharge by day 28 in patients with severe #COVID19 https://t.co/sQkhATkjEd— Antibiotic Steward Bassam Ghanem🆔🔥 (@ABsteward) June 16, 2022
Estudo randomizado | Segurança e eficácia do eptinezumabe para prevenção de enxaqueca em pacientes com 2 a 4 tratamentos preventivos prévios falhos.
21 Jun, 2022 | 12:40hSafety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial – The Lancet Neurology (link para o resumo – $ para o texto completo)
Estudo de caso controle com teste negativo | Efeitos de infecção prévia e vacinação sobre infecções sintomáticas pela variante Ômicron.
19 Jun, 2022 | 17:20hConteúdos relacionados:
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine
Two new studies show vaccination provides additional protection after Covid-19 infection.
Comentário no Twitter
A study in Qatar assessed the effectiveness of previous infection, vaccination, and both against symptomatic SARS-CoV-2 caused by omicron BA.1 and BA.2 and against severe, critical, or fatal #COVID19. https://t.co/bEVD3Y1sUn pic.twitter.com/Y38a0xxead
— NEJM (@NEJM) June 15, 2022
Conselho do FDA é favorável às vacinas contra COVID-19 para crianças mais novas.
19 Jun, 2022 | 17:18hFDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP
Ver também: FDA advisers endorse 1st COVID-19 shots for kids under 5 – Associated Press
Estudo da Pfizer sobre o Paxlovid falha em responder a questões centrais sobre o benefício para populações mais amplas.
19 Jun, 2022 | 15:46hPfizer’s Paxlovid study fails to answer key questions over benefit for broader populations – STAT
Estudo randomizado | Efetividade e segurança de loções, cremes, géis e pomadas emolientes para eczema infantil.
19 Jun, 2022 | 15:45hComunicado de imprensa: The right moisturiser for children with eczema is the one that they like to use, study finds – University of Nottingham
Comentário: Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema – HealthDay
Comentário no Twitter
New: @bee_study led by @riddmj found no difference in effectiveness between the four main types of emollients —lotions, creams, gels, and ointments—for childhood #eczema
The right #moisturizer is the one that children will use. https://t.co/45N5A136Kx
— The Lancet Child & Adolescent Health (@LancetChildAdol) May 24, 2022